Full Press Release Details
EIP Pharma Announces Clinical Study Presentations at the 11th Clinical Trials on Alzheimer's Disease Conference and Provides Update on Phase 2b Clinical Study Enrollment.
CRVO
EIP Pharma Announces Clinical Study Presentations at the 11th Clinical Trials on Alzheimer's Disease Conference and Provides Update on Phase 2b Clinical Study Enrollment
Key Takeaway: EIP Pharma Announces Clinical Study Presentations at the 11th Clinical Trials on Alzheimer's Disease Conference and Provides Update on Phase 2b Clinical Study Enrollment
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
6.8%
average across 6 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
Neflamapimod
Phase 2 · Moderate to Severe Acute Ischaemic Stroke